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Background: The overuse of antimicrobials is recognized as the main selective pressure driving the emergence and
spread of antimicrobial resistance in human bacterial pathogens. Urinary tract infections (UTIs) are among the most
common infections presented in primary care and empirical antimicrobial treatment is currently recommended. Previous
research has identified that a substantial proportion of Irish general practitioners (GPs) prescribe antimicrobials for UTIs
that are not in accordance with the Guidelines for Antimicrobial Prescribing in Primary Care in Ireland. The aim of this trial
is to design, implement and evaluate the effectiveness of a complex intervention on GP antimicrobial prescribing and
adult (18 years of age and over) patients’ antimicrobial consumption when presenting with a suspected UTI.
Methods/design: The Supporting the Improvement and Management of Prescribing for urinary tract infections (SIMPle)
study is a three-armed intervention with practice-level randomization. Adult patients presenting with suspected UTIs in
primary care will be included in the study.
The intervention integrates components for both GPs and patients. For GPs the intervention includes interactive
workshops, audit and feedback reports and automated electronic prompts summarizing recommended first-line
antimicrobial treatment and, for one intervention arm, a recommendation to consider delayed antimicrobial treatment.
For patients, multimedia applications and information leaflets are included. Thirty practices will be recruited to the study;
laboratory data indicate that 2,038 patients will be prescribed an antimicrobial in the study. The primary outcome is a
change in prescribing of first-line antimicrobials for UTIs in accordance with the Guidelines for Antimicrobial Prescribing in
Primary Care in Ireland. The study will take place over 15 months with a six-month intervention period. Data will be
collected through a remote electronic anonymized data-extraction system, a text-messaging system and GP and patient
interviews and surveys. The intervention will be strengthened by the implementation of a social marketing framework
and an economic evaluation.
Trial registration: This intervention is registered at ClinicalTrials.gov, ID NCT01913860.
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Antimicrobial resistance (AMR) is an important and com-
plex public health problem [1]. The spread of AMR has
led to the increased use of reserved antimicrobial agents
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reproduction in any medium, provided the orToday, 80% of antimicrobial prescribing takes place in
the community by general practitioners (GPs) [4]. Ireland
is one of only three countries in Europe where the level
of outpatient antimicrobial prescribing is increasing
[5,6]. Within this context, the inappropriate and over-
prescription of antimicrobials by GPs is a recognized
factor contributing to the spread of AMR [7-10]. The
Guidelines for Antimicrobial Prescribing in Primary Care
in Ireland [11] provide advice on the selection of anti-
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more serious infections. However, despite the widespread
availability of these guidelines, recent research has identi-
fied that less than 40% of outpatient prescriptions for
urinary tract infections (UTIs) are made out according to
first-line recommendations [12].
Urinary tract infections are predominantly caused by a
bacteria; Escherichia coli [6,13,14], and are generally
treated empirically, prior to the results of antimicrobial
susceptibility testing [11,12,15]. Antimicrobial resistance is
now a critical factor in the treatment of UTIs [9,12,16],
the second most common bacterial infection in primary
care [6,12,13,15,17].
Changing prescribing and consumption
antimicrobial behaviours
Antimicrobial resistance is complex [7,18], dynamic [19]
and continuous [20], meaning that no single solution will
manage the problem effectively. Multifaceted interventions
aimed at multiple stakeholders (GP, patients and the wider
community) have been shown to be successful in reducing
inappropriate prescribing [2,21-23] and can bring about
social change by addressing local barriers to change [24].
Patients may have preconceived expectations of the con-
sultation [23], determined by their prior experience within
the practice and the treatment of a recurring condition in
some cases [25]. However, a review of patient-orientated
interventions to improve antimicrobial prescribing con-
cluded that change is better achieved by encouraging health
professionals rather than by educating patients about the
negative aspects of antimicrobials [2]. The GP’s decision to
prescribe antimicrobials should be a balance between the
treatment of the individual in the short term and its harm-
ful impact on society in the long term [19,26]. General
practitioners prescribe antimicrobials to treat (bacterial) in-
fection, to guard against the risk of a missed diagnosis [19],
or because they believe the patient expects this outcome
from the consultation [25]; therefore, to obtain a behav-
ioural change, many factors need to be addressed [27].
Educational interventions aimed at the prescriber, the
GP, have shown some successes. Improvements in over-
all prescribing practices in primary care have been linked
with the use of small interactive workshops with health care
professionals, which provide a greater change in prescribing
behaviours when compared with a passive lecture-style for-
mat [28-31]. An interactive workshop style is more likely to
identify multifactorial causes in inappropriate prescribing,
leading to the provision of tailored behavioural change
methods for GPs [2]. Electronic prescribing prompts have
successfully increased GP adherence to prescribing guide-
lines for a range of common illnesses [32-34]. Electronic
prompts have also been successful in increasing the use of
specific antimicrobial drug choices, such as first-line anti-
microbial treatment for common infections [35]. Currently,prescribing prompts are not commonly available within GP
patient management software systems in Ireland.
The use of audit and feedback of information in conjunc-
tion with other intervention methods (delayed prescribing,
educational material or electronic prompts) has also proven
effective in improving GPs antimicrobial prescribing behav-
iours [2,36]. General practitioners in the UK receive routine
feedback on their prescribing practices and are among the
lowest community prescribers of antimicrobials in Europe
[30,37]. Currently, Irish GPs cannot readily access informa-
tion on their prescribing practices, despite evidence to sug-
gest that feedback can successfully reduce antimicrobial
prescribing in the Irish primary care setting [36].
The use of delayed antimicrobial prescribing for viral in-
fections in primary care in the UK has been credited with
achieving a 50% reduction in antimicrobial use [22,38,39].
Empirical antimicrobial treatment for UTIs is currently
recommended in the Guidelines for Antimicrobial Pre-
scribing in Primary Care in Ireland [11]. However, in at
least 50% of patients with UTIs, an antimicrobial may not
be required, as the infection resolves naturally [40-42].
Qualitative studies investigating attitudes to delayed anti-
microbial prescribing in primary care have indicated that
both patients and GPs are satisfied with this treatment for-
mat and welcome this ‘safety net’ approach as a feasible
treatment strategy [23,43-45].
Between the GP and patient, the communication of
such treatment strategies as delayed prescribing can be
viewed as part of a shared decision-making process [23].
A shared decision-making process can empower patients
through a greater understanding of the issues involved
[46,47]. Shared decision making with delayed prescribing
allows patients to prioritize what they value most; in-
creasing their chances of a quick recovery or reducing
their chances of side effects and reconsultations in the
future [47,48].
The leading systematic review in the area of complex pre-
scribing interventions in primary care called for innovative
intervention methods to be developed [2]. Around 75% of a
general practice’s registered patients will wait in the practice
waiting room each year and the demand for easy-to-
understand healthcare information is increasing [49]. The
use of informative material in GPs waiting rooms, such
as educational videos and interactive games, to create
awareness and explain the problems associated with the
overuse of antimicrobials in primary care, has also been
recommended through the European Antibiotics Aware-
ness Day [50].
Educational videos displayed in the practice waiting
room can also increase patients’ understanding and satis-
faction of their care, as well as empowering patients to
discuss their treatments further with the GP [51,52]. Pre-
vious research examined the effectiveness of a multimedia
campaign in comparison with a static educational brochure
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rooms with patients with low health literacy [53,54]. This
approach was considered novel, effective and acceptable in
improving health care management, by empowering pa-
tients to discuss making positive changes to their treatment
with their GP [54]. Audiovisual messages played in practice
waiting rooms have also proven effective in increasing pa-
tient uptake of vaccines [55].
Mobile phone technology can facilitate rapid and cost-
effective access to a study group of interest to facilitate
data collection. Previous programmes have successfully
used text messages to assess consumption and adher-
ence to antimicrobial treatments with 72% patient par-
ticipation for follow-up [56].
Intervention development overview
Social marketing is the conceptual framework that guided
the development of this intervention, by integrating know-
ledge from such disciplines as psychology, anthropology
and sociology [57-59] with commercial marketing tech-
niques [59-63]. Social marketing interventions address three
key areas: understanding current behaviours; identifying de-
terminants and identifying mechanisms for change [64].
Owing to the intricate factors that influence the deci-
sion to prescribe an antimicrobial, not all strategies will
work with all GPs in all regions [2]. The SIMPle study
focuses on behavioural changes that are feasible and self-
sustaining, given the available resources. The appropriate-
ness of changes and their feasibility within the GP practice
setting were also considered [65].
Formative (qualitative) research explored the culture
of antimicrobial prescribing from both the GP’s and the
patient’s perspective. Through a series of interviews with
GPs (n = 16) and focus groups with patients (n = 35), the
predictors of a GP’s decision to prescribe an antimicrobial
and the patient’s expectation to receive an antimicrobial
were explored. The questions were guided by a combin-
ation of theoretical frameworks, the transtheoretical model
[66] and the buyer behaviour decision-making model [67],
which together explored six key areas: the stage of change,
consequences, trade-offs, other influences, segmentation
and competition [68].
As a result of this formative research process, five core
outcomes were achieved:
1. The expectations of the patient relating to the UTI
consultation with GPs were characterized.
2. The factors that impact the GPs decision to
prescribe an antimicrobial were defined.
3. The key messages central to the design and
development of this intervention were specified for
both the GP and the patient.
4. The results supported the development of
quantitative evaluation components, such as abaseline questionnaire to monitor changes in
knowledge, attitudes and awareness for both GP
and patient.
5. The behavioural theoretical framework underpinning
the design and development of this complex
intervention was defined.
The multiple interactive components of this interven-
tion were informed by both the peer-reviewed literature
and formative research. In short, the SIMPle study will
integrate:
 A professional development programme for the GP,
which includes interactive workshops, audit and
feedback reports on antimicrobial prescribing and
electronic antimicrobial prescribing prompts to
improve the quality of prescribing. The quality of
prescribing is defined within this study as the
prospective prescribing of first-line antimicrobials in
accordance with the Guidelines for Antimicrobial
Prescribing in Primary Care in Ireland.
 Delayed antimicrobial prescribing for UTIs in one
study arm, to decrease the consumption of
antimicrobials.
 A supportive framework to inform patients of AMR
through multimedia applications within the waiting
room of the GP.
 Novel e-health technology, which includes an
electronic data extraction system that will remotely
collect anonymized data from all consultations with
patients diagnosed with a UTI by the GPs and mobile
health technology to monitor and record antimicrobial
consumption behaviour of patients.
By integrating this intervention into routine care and
making all material freely available at the end of the
intervention, the SIMPle study strives to be sustainable
and self-promoting and, thereby, implemented in pri-
mary care in Ireland beyond the intervention period.Aim and objectives
Aim of the SIMPle study
To design, implement and evaluate the effectiveness of a
complex intervention on GP antimicrobial prescribing and
adult (18 years of age and over) patients’ antimicrobial con-
sumption when presenting with a suspected UTI.Primary objective
To increase the number of first-line antimicrobial pre-
scriptions, as recommended in the Guidelines for Anti-
microbial Prescribing in Primary Care in Ireland (2011),
for suspected UTIs in primary care by 10% in adult
patients.
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1. To compare the effect of the intervention on the
frequency of antimicrobial prescribing and
antimicrobial consumption in patients presenting
with a UTI.
2. To measure the uptake and impact of delayed
antimicrobial prescribing for UTIs and the impact
of this treatment approach on UTI GP
reconsultation visits.
3. To assess a change in cognitive beliefs (knowledge
and attitudes) of GPs related to antimicrobial
prescribing.
4. To conduct a cost-effectiveness and process
evaluation of the SIMPle intervention.
5. To compare the prescribing rates of the intervention
arms with regional UTI antimicrobial prescribing rates.
Methods and design
Setting
The cluster for this intervention is the practice, and all
GPs within each practice will be invited to participate.
The baseline population for recruitment of patients will
be formed by all practices in the West of Ireland who
submit urine samples to the Galway University Hospitals
(GUH) laboratory. The most popular patient management
software system was chosen, because the SIMPle study
builds on remote data extraction, the provision of audit
and feedback reports and computer prompts integrated
within the GP’s patient management software system. If
successful, the intervention could be integrated within the
other patient management software systems, of which
there are five. In summary, practice eligibility criteria are
such that all practices must have the specified patient
management software system and submit urine samples
to the GUH laboratory.
Study design
This study will be undertaken in four phases: Phase 1,
baseline data collection; Phase 2, GP intervention; Phase 3,
patient intervention and Phase 4, endpoint data collection.
The study design is summarized in Figure 1.
Implementation
Computerized remote data extraction is facilitated by
the Irish Primary Care Research Network (iPCRN) [69]
and patient data are identified through the appropriate
coding of suspected UTI consultations in the patient
management software system. To promote and encour-
age consultation coding, which is currently not routine
practice, the intervention will be preceded by a coding
workshop at the beginning of Phase 1. All practices will
be required to register with the iPCRN during or before
the coding workshop. Practices will be monitored fortwo months after the delivery of the workshop to estab-
lish uptake of coding, whilst also facilitating a baseline
data collection period (Phase 1). Phase 2 will begin with
an interactive workshop (intervention arms A and B),
which will introduce the intervention components spe-
cific to each arm. Phase 3 will see the roll-out of the pa-
tient education in all of the practices. The antimicrobial
prescribing within each practice will be monitored for six
months during Phases 2 and 3 through audit and feedback
reports. Evaluation of the impact of the intervention will
be carried out in Phase 4.
Practice identification and randomization
A list of all practices submitting urine samples to GUH
was obtained and practices were contacted by phone to
establish what patient management software system they
used. Practices using the selected patient management
software system were thereby identified. The first 30 prac-
tices were invited to participate by an invitation letter,
which provided an overview of the study, benefits for par-
ticipation and the contact details of the research team.
Within 10 days of receipt of this invitation, practices
were telephoned to determine their interest and willing-
ness to participate in the study. If a practice declined to
participate, the reason for not agreeing was recorded
and that practice was replaced by another from the eligi-
bility list. This process continued until 30 practices were
enrolled. Practices were then randomized to intervention
and control arms, using a list of computer-generated num-
bers. The workshop facilitators were blinded to the alloca-
tion throughout the delivery of the coding workshops in
Phase 1.
Patient eligibility
All patients are eligible if aged 18 years and over and
presenting with symptoms of an UTI, as determined by
the GP through the consultation coding.
Patient enrolment
All patients consulting in the participating practices will
be informed of the study through information posters in
the waiting area from Phase 1.
In Phase 2, GPs will be encouraged to submit a urine
sample from each patient presenting with a suspected
UTI to the GUH laboratory and request the patient’s
mobile telephone number during the consultation. The
patient’s mobile telephone number will be recorded on
the laboratory diagnostic request form submitted with
the urine sample to the GUH laboratory. Mobile tele-
phone numbers will be collected on a daily basis from
this laboratory. Each mobile telephone number will be
entered into a computer program, which will generate
automated text messages. The first text message will con-
firm consent.
Figure 1 Study design.
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Primary outcome: adherence to the guidelines for
antimicrobial prescribing in primary care in Ireland
(control − intervention arm a)
Previous research has established that 56% of UTI patients
receive an antimicrobial, with only 38% of prescriptions
made out for the recommended first-line treatment [8].
Sample size calculations are based on an absolute 10%increase in first-line prescriptions according to guidelines
(primary outcome).
Additional assumptions for sample size calculations are:
 Power of 80% and α of 5%.
 Practice attrition is dependent on the completeness
of consultation coding, which will be monitored and
corrected during Phase 1.
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consultations will be included.
 Improvement in the control group due to
participation in the coding workshops has
been anticipated.
 An intracluster correlation (ICC) of 1% was
obtained from a previous study in this area [6,12].
A total sample size of 920 patients recruited from 20
practices gives a power of 80% to detect a significant
change in the proportion of patients to receive first-line
antimicrobial when treated for UTI when the ICC is 1%.Feasibility
According to the most recent laboratory urine sample sub-
mission (personal communication, 2012), an average of 364
urine samples (median 257, range 25 to 1,162) per year per
eligible practice are sent in to the GUH laboratory. Consid-
ering that the intervention will run over a six-month period
(Phases 2 and 3) and without any adjustment for the total
number of UTI-related consultations, an estimated 3,640
urine samples will be submitted from 20 participating prac-
tices during this period. If 56% of these patients are pre-
scribed an antimicrobial over a six-month period, a total of
2,038 patients will be prescribed an antimicrobial.Secondary outcome: decrease in the quantity of
consumption (control − intervention arm B)
To estimate the potential power to detect this secondary
outcome, an additional sample size calculation was car-
ried out.
 56% of the patients presenting with a UTI, and for
whom a urine sample was submitted for
microbiological analysis, received a prescription [8].
 A 20% decrease in consumption can be achieved
through delayed prescribing [42].
Taking account of the cluster effect and based on pre-
vious ICC estimates, a total sample size of 240 patients
recruited from 20 practices gives a power of 80% to detect
a significant change in the proportion of patients who re-
duce antimicrobial consumption through delayed prescrib-
ing if the ICC is 1%.Intervention
Overview of SIMPle intervention
The SIMPle intervention incorporates components that
address GP and patient behaviours relating to antimicro-
bial prescribing and consumption. Each component is
discussed individually. Table 1 provides an overview of all
intervention components.GP components
Intervention workshops
A coding workshop will be delivered to all practices at
the beginning of Phase 1. Routine coding for UTIs using
the International Classification of Primary Care code (U71:
‘cystitis, urinary infection, other’) will be demonstrated.
The advantage of routine coding of UTI consultations will
be to facilitate the generation of electronic audit and feed-
back reports, which will be extracted through the iPCRN
system (see further).
Contact information for GPs (for example, mobile tele-
phone numbers, email addresses) will also be collected to
facilitate reminders to code throughout the study period.
Phase 2 will begin with an interactive workshop for inter-
vention arms A and B. The interactive workshops promote
changes (where necessary) in antimicrobial prescribing for
the treatment of UTIs by presenting an overview of pre-
scribing and AMR, discussing the role of the GP in the
spread of AMR and the potential positive impact of pre-
scribing according to guidelines.
In addition, the interactive workshop delivered to prac-
tices in intervention arm B will support the GPs in recom-
mending delaying antimicrobial treatment by 48 hours
where appropriate. Based on the information provided in
the workshop, the GP can discuss the benefits of delayed
antimicrobial treatment for UTIs with the patient. This
two-way communication will encourage patients to make
an informed decision on their treatment. The decision
to delay treatment will be shared between the GP and
the patient.
The workshops will be delivered to each practice by
members of the research team. General practitioners at-
tending the workshops can receive continued professional
development recognition for their participation from the
Irish College of General Practitioners.
Computer prompt application
For intervention arms A and B, a computer prompt has
been developed for use within the selected GP practice
management software system. This prompt summarizes
the recommendations for first-line antimicrobial treatment
and will appear on the computer screen when the GP en-
ters the International Classification of Primary Care code
(U71) for ‘cystitis, urinary infection, other’. In addition, for
practices in intervention arm B, the prompt will include a
recommendation to consider delayed antimicrobial pre-
scribing. In intervention arms A and B this prompt will
also remind the GP to collect patients’ mobile telephone
numbers.
Electronic audit and feedback reports
Electronic audit and feedback reports will be available to
download by GPs through the iPCRN. These reports will
provide the practice with information on antimicrobial
Table 1 Overview of SIMPle intervention components
Intervention component Study arm Description Primary objectives Secondary objectives
GP focused
Coding workshop All arms Demonstrate the purpose of electronically
coding UTI consultations using coding
guidelines (International Classification of
Primary Care code U71) and how to
implement uniform coding in routine practice.
Promote routine uniform consultation
coding for UTIs.
Gather baseline practice data and knowledge
and attitudinal data (questionnaires).
Interactive workshop A Intervention arm A Raise the profile of GPs’ antimicrobial prescribing
behaviours and their role in the broader issue of AMR.
Encourage GPs to become more aware of their
antimicrobial prescribing behaviours through
discussion of their role in the development of AMR.
Process evaluation
Provide guidance on antimicrobial prescribing
through adherence to guideline for UTI.
Interactive workshop B Intervention arm B In addition to the core components of interactive
workshop A, the recommendation to delay
antimicrobial prescribing for UTIs facilitated through
shared decision making will be promoted.







A monthly report will be available (electronically) to
practices summarizing their antimicrobial prescribing
patterns for UTIs and antimicrobial resistance
patterns of E. coli.
To provide a comparison of antimicrobial
prescribing for UTIs between practices.
To provide an overview of antimicrobial
resistance patterns in E. coli causing UTIs.
Stakeholder awareness Information about the intervention and the issue of
AMR will be provided to other stakeholders;
pharmacists, practice receptionists and practice nurses.




Intervention arm A Upon entry of the uniform UTI code, automated
electronic prompts will appear on the GPs
computer screen.
Provide the recommended antimicrobial
treatment for a UTIs.
Remind the GP to collect urine samples and
patients’ mobile telephone numbers.
Intervention arm B Provide the recommended antimicrobial
treatment for a UTI and suggest
delayed prescribing.
Patient focused components
Informational leaflets Intervention arms
A and B
Leaflets will outline the aim of the SIMPle study and
highlight issues relating to consuming antibiotics.
Intervention arm B patients will receive additional
information, outlining the benefits of delayed
prescribing for UTIs.
To increase awareness of the side effects,
resistance and lack of the availability of
new antibiotics.
To inform the patient of the study. To
support the use of delayed prescribing for UTIs
(patients in intervention group B only).
Educational infomercial An educational video will be displayed in practice
waiting rooms. The video will outline the key issues
associated with AMR to patients.
GP and patient focused components
Website Intervention arms
A and B
The website will provide more information on
the issues of AMR.
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information from the other practices participating in the
intervention. AMR patterns of bacteria causing UTIs will
also be presented to the practice. The audit and feedback
reports will be available to intervention arms A and B
from the start of Phase 2, and to the control arm at the
end of Phase 3.
Stakeholder awareness
All relevant gatekeepers who are directly or indirectly in-
volved in the implementation of the intervention will re-
ceive information on the SIMPle study. These gatekeepers
include practice staff, such as the receptionist, practice
managers and nurses. Local pharmacists will also be in-
formed of the intervention prior to its launch. The use of
delayed antimicrobial prescribing for UTIs will be com-
municated to local pharmacists to provide support in the
event of a patient requiring further information.
Patient components
The key messages about antimicrobials underlying the
design of all patient focused materials are:
1. Taking an antimicrobial for an infection now
increases your chances of having a resistant bacterial
infection in the future.
2. Owing to the development of AMR, we are running
out of antimicrobial treatment options for more
serious bacterial infections.
Informational leaflets
Patients presenting with symptoms of a UTI to their GP
will receive an information leaflet describing the study, the
purpose of the collection of their mobile phone numbers,
facts about antimicrobials and the issues surrounding the
development of AMR in bacteria. Patients visiting prac-
tices from intervention arm B will receive the leaflet with
additional information on delayed prescribing of antimi-
crobials as a potential treatment option for UTIs.
Patient education
An infomercial (information commercial) explaining the
two key messages (as previously outlined) has been devel-
oped for display in practice waiting rooms. An infomercial
is a short video representation of information, data or
knowledge intended to present complex information quick-
ly and clearly. The infomercial will be displayed in an en-
closed and fixed iPad in the practice waiting room. There
will also be an option to play an AMR-themed game on this
iPad, which will contain the same two messages as stated
above. All intervention practices will be offered an iPad for
their waiting room at the start of Phase 3 (Figure 1). The
impact of this component on antimicrobial prescribing and
consumption will be evaluated in comparison with Phase 2.Both the infomercial and the game will be made freely
available for download at the end of Phase 4.
The control arm
To gather comparable data on UTI consultations, practices
in the control arm will complete a coding workshop at the
beginning of Phase 1. For the remainder of the intervention,
the control arm will provide ‘usual care’ and will receive
their audit and feedback reports at the end of intervention
Phase 3. Practices in the control arm will also submit urine
samples from UTI patients and request patients’ mobile
telephone numbers for the duration of the intervention.
Ethical approval
Ethical approval including a patient opt-out method-
ology was obtained from the Irish College of General
Practitioners.
Informed consent
Informed consent for practice participation in the inter-
vention and for the remote extraction of anonymized
UTI patient consultation data through the iPCRN will
be obtained from the practices at the start of the coding
workshop in Phase 1. Each practice will also receive posters
to display in their waiting room to inform patients of the
practice’s decision to participate in the SIMPle study. The
GP will request the patient’s mobile telephone number and
outline the aim of the study during the UTI consultation.
Patients will be required to confirm their consent by reply-
ing to the first text message they receive before continuing
with the text-messaging process.
Quantitative data collection
Data collection will involve five quantitative compo-
nents: consultation data obtained through the iPCRN;
questionnaire data from the GPs, along with a practice
profile from the practice manager; Health Service Execu-
tive Primary Care Reimbursement Services (HSE-PCRS)
prescribing data; and patient follow-up information through
text messages. Data for the GPs will be collected at the
beginning of Phase 1, immediately after the patient educa-
tion intervention (Phase 3) and after a six-month follow-up
(Phase 4). The collection of patient data will continue
throughout Phases 2 and 3.
Consultation data
For the purpose of the intervention, UTI consultation data
will be extracted remotely through the iPCRN. Extracted
anonymized consultation information will be comprehen-
sive and will include, at a practice level:
 Total number of consultations per month;
 Total number of consultations for UTIs per month
(coded U71);
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 Number of times an audit was generated
(to monitor coding).
For the patients, the following information will be
collected:
 Consultations (numbers, dates);
 UTI consultations (dates);
 Urine sample results (date, outcome, resistance profile);
 Antimicrobial prescribing (type, date, dosage);
 Other prescribed medication (type, date, dosage);
 Demographic data including age, sex, medical card
status and comorbidities (if coded).Questionnaires
Additional information collection will take place at primary
points throughout the intervention, including the adminis-
tration of a questionnaire to collect data on knowledge and
attitudes towards antimicrobial prescribing by GPs. This
questionnaire will be administered to GPs at the beginning
of Phase 1, at the coding workshop and at the end of Phase
3, to measure potential changes in knowledge, attitudes
and behaviours of GPs in each arm. A practice profile will
be completed at the beginning of Phase 1, to determine
number of whole-time equivalent GPs and practice size.Health Service Executive Primary Care Reimbursement Services
The HSE-PCRS provides free health services under the
General Medical Services scheme. Approximately 30% of
the Irish population is entitled to free medical care, in-
cluding medication under this scheme. Regional prescrib-
ing data from practices in the study will be compared with
HSE-PCRS data [70].Follow-up data
Evaluative information from the patients will be obtained
via text message. These text messages will require a min-
imal response (at no cost) from the patient and will be used
to assess actual consumption of the prescribed antimicro-
bial. Patients can discontinue receiving these text messages
at any time by replying STOP.Online survey
After clearance of symptoms, assessed via text messaging,
patients who were followed up will be invited to complete a
brief online survey. This survey includes questions regard-
ing the patient’s attitudes to antimicrobials, consumption of
antimicrobials and awareness of the potential implications
of AMR. Patients will be incentivized to complete the on-
line survey.Quantitative data analysis
Data comparisons will be made between the start and
end of the intervention. To assess sustainability, an add-
itional comparison will be made six months after the
end of the intervention. An overview of the data col-
lected through the iPCRN, as outlined in data collection,
will be presented for both practice and patient variables.
Data will be presented and compared between each arm.
Patients’ characteristics will be compared between the
group who were followed up by text messaging and the
group who did not participate in text messaging.Primary outcome: adherence to the guidelines for
antimicrobial prescribing in primary care in Ireland
Comparison of antimicrobial prescription data will be
made between control and intervention arm A.
 Each consultation will be categorized according to
whether an antimicrobial was prescribed (yes/no)
and if so, whether first-line antimicrobials were
prescribed (yes/no).
 Antimicrobial prescribing rates will be determined
for each intervention arm per month for first-line,
second-line and other antimicrobials as specified in
the Guidelines for Antimicrobial Prescribing in
Primary Care in Ireland.
 The proportion of antimicrobial prescribing according
to first-line treatment for each intervention arm will
be calculated by determining the number of first-line
prescriptions as a percentage of the total number of
antimicrobial prescriptions for UTIs.Outcome: frequency of antimicrobial prescribing
and consumption
The frequency of antimicrobial prescribing will be com-
pared between the control and each intervention arm
(arms A and B).
 Consultations will be analyzed according to whether
an antimicrobial was prescribed or not (yes/no).
 The prescription rates per group per month for each
antimicrobial group will be calculated as the number
of antimicrobial prescriptions per 1,000
consultations per month.
 Comparison of the overall reduction over the period
of the intervention will be based on the percentage
of consultations where an antimicrobial was
prescribed at the start of the intervention, as
compared with the end.
The frequency of antimicrobial consumption will be com-
pared between intervention arms A and B, according to
their response to the text messages.
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The frequency of delayed prescribing measured as a per-
centage of overall prescribing for UTIs will be compared
between the intervention arm B and the control. Com-
pliance with delayed prescriptions will be measured by
the percentage of patients who waited the recommended
48 hours (information obtained by text message).
Outcome: reconsultation visits
Reconsultation will be determined by the number of recon-
sultation UTI visits to the GP within one month of initial
treatment.
Outcome: change in cognitive beliefs (knowledge and
attitudes) Change in cognitive beliefs at the start of Phase
1 to the end of Phase 3 will be assessed by comparing the
percentage change in cognitive beliefs (knowledge and at-
titudes) relating to antimicrobial prescribing behaviour be-
tween the three arms.
Outcome: impact of patient educational material
A potential additional impact of patient education will be
evaluated by comparing prescribing and consumption be-
tween A1 and B2 (no support) and A2 and B1 (support)
(see Figure 1).
Method of quantitative data analysis
Quantitative analysis will be undertaken using SPSS for
Windows release 20.0 (SPSS Inc., Chicago, IL, USA) and
Stata 11 (Stata Corporation, Texas). Multilevel analysis will
be performed using MLwiN version 2.21 software and
cost-effectiveness analysis will be conducted using Excel
and Stata 11. Statistical significance will be set at the 5%
level for all outcomes.
Multivariate analysis will examine intervention and con-
trol arm changes from baseline measures and will follow
the principle of intention to treat. Outcomes will be com-
pared between intervention (arms A and B) and the con-
trol arm, using a multilevel logistic modelling approach to
control for baseline prescribing as well as other confound-
ing variables at patient and practice level. All statistical
analysis will be undertaken in accordance with current
guidelines for randomized controlled trials [71].
Qualitative data collection
Qualitative data will be used to assist in the process
evaluation of the intervention.
Data will be collected through semistructured interviews
with GPs, practice staff and patients from intervention
and control practices at the end of the study period. GPs
and practice staff will be randomly selected from partici-
pating practices (n ≈ 15 to 40). Patients can opt in to par-
ticipate by providing their contact details at the end of the
online patient survey.The intervention will be evaluated from the GP’s
perspective:
 Changes in GPs’ attitudes towards antimicrobial
prescribing;
 How the intervention is implemented;
 How the intervention is integrated with other
practice activities;
 How well GPs understand the intervention;
 Whether elements of the intervention are
particularly important or problematic.
The intervention will be evaluated from the patient’s
perspective:
 Satisfaction with the GP consultation;
 The process of care;
 Evaluate the intervention components as
stated above.
Qualitative data analysis
Analysis of qualitative data will be completed using NVivo-
9 qualitative data analysis software. Data analysis will fol-
low an inductive approach through thematic analysis. A
cross-comparison of qualitative analysis will be conducted
by two team members, one not directly involved in the
interview process; along with active discussion of findings
with the wider project team, this will help ensure the
rigour of the thematic analysis.
Economic evaluation
The economic cost of UTIs in primary care consists of
direct costs associated with health care utilization and
drug costs, indirect costs associated with lost product-
ivity, premature mortality and intangible costs, such
as the cost of pain and discomfort to the individual. In
addition, increasing resistance to antimicrobials has im-
plications for the economic costs of UTIs. In particu-
lar, potential treatment failure as a result of resistance
means an increase in the use of more expensive al-
ternative treatments, as well as potential increases in
healthcare utilization.
The economic analysis will take a two-staged approach.
1. A within-intervention analysis will be conducted,
using the cost per rate of first-line antimicrobial
prescribing to assess the costs and effects of the
intervention arms in comparison with the
control arm.
2. Modelling analysis of the impact of prescribing
adherence will be undertaken. This will
facilitate the identification, valuation and
extrapolation of the wider impact of prescribing
adherence.
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 Intervention costs: direct costs will include
intervention costs, capital costs, cost of providing
workshops, learning materials, leaflets and any
other materials.
 Health services costs include GP consultation time,
use of hospital services, additional laboratory service
costs and prescription costs.
The cost-effectiveness will be assessed by relating the
mean differential cost per practice between the interven-
tion arms and the control, to their differential effectiveness.
Incremental cost-effectiveness ratios will be calculated and
subjected to sensitivity analysis. The primary outcome will
be cost per prescription of first-line antimicrobials.
In addition, it is likely that some of the costs and conse-
quences of the intervention will continue after the interven-
tion period has ended, for which an additional economic
evaluation will be performed. This modelling analysis will
facilitate the extrapolation of the costs and outcomes over
time with data obtained from the within-intervention ana-
lysis. Where there are evident gaps in the available data,




Utilizing a multidisciplinary perspective and social mar-
keting conceptual framework, this study will contribute an
understanding of the key behaviours and social norms that
motivate change in GPs antimicrobial prescribing and pa-
tient antimicrobial consumption behaviours. The interven-
tion will provide an evaluation of the different parts and
thereby provide evidence to implement individual or all
parts of the intervention beyond the study area and period.
Anticipated publications
 A qualitative study of the formative research that
underpinned the development of the intervention.
 A description of the multidisciplinary intervention
to improve quality and quantity of antimicrobial
prescribing in primary care (protocol).
 A quantitative analysis of the impact of the
intervention on the quality and quantity of
antimicrobial prescribing in primary care.
 An economic analysis of the intervention to improve
antimicrobial prescribing in primary care including
future cost estimates.
 Given the community focus of this research,
findings will be disseminated through local print and
online media, to include the widest possible
audience.Limitations of the study
The method of data collection used requires a coding
workshop to improve routine consultation coding for UTIs
in all practices participating in the intervention, including
those in the control group. The inclusion of the control
group in the coding workshop may affect the outcome;
however antimicrobial treatment was not discussed at these
workshops. To limit this bias, researchers delivering the
workshops were blinded as to randomization of practices
to intervention and control. This bias is anticipated to
increase awareness in the control group, resulting in a
potentially smaller difference between intervention and
control arms.
Computerized remote data extraction will be used to
assess differences between the intervention and control
arms. Data analysis will not be blinded. However, as the
outcome is an absolute comparison in first-line prescrip-
tions of antibiotics, before and after the intervention, the
risk of bias is minimal.
The use of patient mobile telephone numbers for evalu-
ation purposes, while novel and direct, introduces selection
bias, owing to different levels of mobile phone penetration
and familiarization with their use. For research evaluation
purposes, however, the implementation of follow-up by
mobile telephone technology allows evaluation of con-
sumption (and thereby the impact of delayed prescribing)
rather than simply the evaluation of prescribing behaviour
by GPs. However, since the sample can be related back to
the source population and the selection bias can be esti-
mated, the final evaluation can be considered within this
context.
Trial status
The intervention was registered with ClinicalTrials.gov
on 26 July 2013, ID number NCT01913860. At the time
of protocol submission, geographical areas and practices
have been identified and contacted, and 30 practices
have been recruited.
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